When was Sonnet BioTherapeutics founded?

Sonnet BioTherapeutics was founded in 2011 and raised its 1st funding round 8 years after it was founded.

Where is Sonnet BioTherapeutics located?

Sonnet BioTherapeutics is headquartered in Princeton, United States.

Who is the current CEO of Sonnet BioTherapeutics?

Pankaj Mohan of Sonnet BioTherapeutics. They have also founded 1 company.

How many employees does Sonnet BioTherapeutics have?

As of Oct 31, 2026, the latest employee count at Sonnet BioTherapeutics is 11.

Is Sonnet BioTherapeutics a funded company?

Sonnet BioTherapeutics is a funded company, having raised a total of $750K across 4 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on May 14, 2019.

When was the latest funding round of Sonnet BioTherapeutics?

Sonnet BioTherapeutics' latest funding was a $***** Post IPO round on Dec 10, 2024, with participation from 0 investor.

What is the annual revenue of Sonnet BioTherapeutics?

Annual revenue of Sonnet BioTherapeutics is between $1M and $10M as on Sep 30, 2025

Where does Sonnet BioTherapeutics rank among its competitors?

Sonnet BioTherapeutics ranks 313th amongst 3405 active competitors, of which 1135 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Sonnet BioTherapeutics?

Sonnet BioTherapeutics' top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Sonnet BioTherapeutics - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of immunotherapies for the treatment of cancer. The company has proprietary FHAB™ (Fully Human Albumin Binding) technology that empowers the development of innovative targeted biologic drugs with enhanced single- or bi-specific mechanisms. The company's lead compound is SON-1010 for solid tumors.

Website: sonnetbio.com
Email ID: *****@sonnetbio.com
Phone Number: +1 **********

Key Metrics

Founded Year

2011

Location

Princeton, United States

Stage

Public

Total Funding

$750K in 4 rounds

Latest Funding Round

Post IPO, Dec 10, 2024, $*****

Investors

East West Capital Partners

Ranked

313^th among 3405 active competitors

Annual Revenue

$1M - $10M as on Sep 30, 2025

Employee Count

11 as on Oct 31, 2026

Similar Companies

Jazz Pharmaceuticals & 3060 more

Exit Details

Public

View Sonnet BioTherapeutics' full profile

Sonnet BioTherapeutics is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Sonnet Biotherapeutics Holdings, Inc. CIN: 1106838 , United States, Active		$1M - $10M (As on Sep 30, 2025)	-	-
SONNET BIOTHERAPEUTICS HOLDINGS, INC. CIN: 20-2932652 , United States, Active	Oct 20, 1999	-	12 (As on Sep 30, 2023)	-
SONNET BIOTHERAPEUTICS INC CIN: 473788572 , United States, Active	Dec 31, 1999	-	13 (As on Dec 31, 2024)	-

Sonnet BioTherapeutics got listed on Apr 02, 2020.

Click here to take a look at Sonnet BioTherapeutics's IPO in detail

Sonnet BioTherapeutics has raised a total funding of $750K over 4 rounds. Its first funding round was on May 14, 2019. Sonnet BioTherapeutics has 1 institutional investor.

Here is the list of recent funding rounds of Sonnet BioTherapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 10, 2024	9138967	Post IPO	2007739	8870396	3356598	9526561
Jul 17, 2023	9829259	Post IPO	3158208	1677610	9619539	3739983
Aug 25, 2020	3096762	Post IPO	9295574	5326475	9602111	2502025

Access funding benchmarks and valuations. Sign up today!

View details of Sonnet BioTherapeutics's funding rounds and investors

The founders of Sonnet BioTherapeutics is Pankaj Mohan. Pankaj Mohan is the CEO of Sonnet BioTherapeutics.

Here are the details of Sonnet BioTherapeutics' key team members:

Pankaj Mohan: Founder & CEO & Chairman  of Sonnet BioTherapeutics.
Contact Info: 1 email address

View details of Sonnet BioTherapeutics's Founder profiles and Board Members

Sonnet BioTherapeutics' employee count trend

Sonnet BioTherapeutics has 11 employees as of Oct 26. Here is Sonnet BioTherapeutics's employee count trend over the years:

Employee count trend for Sonnet BioTherapeutics

Uncover Sonnet BioTherapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Sonnet BioTherapeutics include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Sonnet BioTherapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, Leaps by Bayer & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
313th	Sonnet BioTherapeutics 2011, Princeton (United States), Public	Developer of immunotherapies for the treatment of cancer	$750K	East West Capital Partners	49/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Sonnet BioTherapeutics's competitors? Click here to see the top ones

Sonnet BioTherapeutics has made no investments or acquisitions yet.

Here is the latest report on Sonnet BioTherapeutics's sector:

Free

Oncology - Sector Report

Edition: August, 2026 (74 Pages)

View all reports related to Sonnet BioTherapeutics

Media has covered Sonnet BioTherapeutics for a total of 8 events in the last 1 year, 1 of them has been about company updates and 1 about partnerships.